Sold as Relafen. Every FDA application for this active ingredient: 1 branded and 14 generic.
As of Nov 16, 2026, FDA lists 15 applications for Nabumetone (sold as Relafen), first approved Dec 24, 1991, with 0 new uses approved and 0 published complete response letters.
| Relafen Ds | Part D | $11.9M | +452% | 1,500 |
| Nabumetone | Part D | $9.7M | -3% | 202,919 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| Effect of the Bioheat Patch on Pain Following the HyFoSy ProcedurePelvic Pain, Infertility · Assaf-Harofeh Medical Center | Not applicable | Not yet recruiting | Jul 24, 2025 |
| Dec 24, 1991 | RelafenNDA 19583 · New molecular entity | Smithkline Beecham | 16 | Discontinued |
| May 26, 2000 | NabumetoneANDA 75189 | Impax Labs Inc | 11 | Discontinued |
| Jun 6, 2000 | NabumetoneANDA 75179 | Copley Pharm | 0 | Discontinued |
| Feb 25, 2002 | NabumetoneANDA 75280 | Chartwell Rx | 5 | Marketed |
| Feb 25, 2002 | NabumetoneANDA 75590 | Epic Pharma LLC | 8 | Discontinued |
| Jan 24, 2003 | NabumetoneANDA 76009 | Chartwell Molecules | 5 | Marketed |
| Mar 7, 2008 | NabumetoneANDA 78671 | Invagen Pharms | 3 | Marketed |
| Sep 24, 2008 | NabumetoneANDA 78420 | Sciegen Pharms | 3 | Marketed |
| Feb 27, 2009 | NabumetoneANDA 79093 | Tp Anda Holdings | 3 | Discontinued |
| Jul 12, 2010 | NabumetoneANDA 90516 | Aurobindo Pharma USA | 3 | Discontinued |
| Jan 12, 2011 | NabumetoneANDA 90445 | Annora Pharma | 3 | Marketed |
| Jun 13, 2011 | NabumetoneANDA 91083 | Watson Labs | 4 | Marketed |
| Dec 30, 2011 | NabumetoneANDA 90427 | Pharmazone | 3 | Discontinued |
| Aug 30, 2019 | NabumetoneANDA 203166 | Lgm Pharma | 2 | Marketed |
| Jan 7, 2025 | NabumetoneANDA 219118 | Novitium Pharma | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA